Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study-Reference-Cited by-同舟云学术

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study

Published:2020-04 Issue:4 Volume:39 Page:300-309
ISSN:1053-2498
Container-title:The Journal of Heart and Lung Transplantation
language:en
Short-container-title:The Journal of Heart and Lung Transplantation

Author:

Sitbon Olivier,Chin Kelly M.,Channick Richard N.,Benza Raymond L.,Di Scala Lilla,Gaine Sean,Ghofrani Hossein-Ardeschir,Lang Irene M.,McLaughlin Vallerie V.,Preiss Ralph,Rubin Lewis J.,Simonneau Gérald,Tapson Victor F.,Galiè Nazzareno,Hoeper Marius M.

Publisher

Elsevier BV

Subject

Transplantation,Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference17 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

3. Risk stratification and medical therapy of pulmonary arterial hypertension;Galiè;Eur Respir J,2019

4. Assessing risk in pulmonary arterial hypertension: what we know, what we don't;Benza;Eur Respir J,2017

5. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension;Boucly;Eur Respir J,2017

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension;European Journal of Medicinal Chemistry;2024-12

2. Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus;Vascular Pharmacology;2024-09

3. Risk stratification and treatment goals in pulmonary arterial hypertension;European Respiratory Journal;2024-08-29

4. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension;European Respiratory Journal;2024-08-29

5. Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: a post-hoc analysis of the GRIPHON study;The Journal of Heart and Lung Transplantation;2024-08